Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19

被引:0
|
作者
Arnaldos-Carrillo, Maria [1 ,2 ,3 ]
Noguera-Velasco, Jose Antonio [1 ,2 ,3 ]
Martinez-Ardil, Isabel M. [7 ]
Riquelme-Perez, Alejandro [2 ,6 ]
Cebreiros-Lopez, Iria [1 ,2 ,3 ]
Hernandez-Vicente, Alvaro [2 ]
Ros-Lucas, Jose Antonio [8 ,9 ]
Khan, Amjad [11 ]
Bayes-Genis, Antoni [6 ,10 ]
Pascual-Figal, Domingo [2 ,3 ,4 ,5 ,6 ]
机构
[1] Hosp Clin Univ Virgen de la Arrixaca, Clin Lab Serv, Murcia, Spain
[2] Univ Murcia, Murcia, Spain
[3] IMIB Pascual Parrilla, Murcia, Spain
[4] Hosp Clin Univ Virgen de la Arrixaca, Cardiol Serv, Murcia, Spain
[5] Ctr Nacl Invest Cardiovasc CNIC, Madrid, Spain
[6] CIBER Cardiovasc, Madrid, Spain
[7] Serv Murciano Salud, Family & Community Med, Murcia, Spain
[8] Hosp Clin Univ Virgen de la Arrixaca, Pneumol Serv, Murcia, Spain
[9] Univ Catolica Murcia UCAM, Murcia, Spain
[10] Hosp Universitari Germans Trias & Pujol, Heart Inst, Barcelona, Spain
[11] Univ Oxford, John Radcliffe Hosp, Radcliffe Dept Med, Nuffield Div Clin Lab Sci NDCLS, Oxford, England
来源
MEDICINA CLINICA | 2023年 / 161卷 / 05期
关键词
COVID-19; pneumonia; sST2; Risk stratification; ST2;
D O I
10.1016/j.medcli.2023.04.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Soluble suppressor of tumorigenicity-2 (sST2) is a biomarker for heart failure and pulmonary injury. We hypothesize that sST2 could help predict severity of SARS-CoV-2 infections. Methods: sST2 was analyzed in patients consecutively admitted for SARS-CoV-2 pneumonia. Other prognostic markers were also measured. In-hospital complications were registered, including death, ICU admission, and respiratory support requirements. Results: 495 patients were studied (53% male, age: 57.6 +/- 17.6). At admission, median sST2 concentrations was 48.5ng/mL [IQR, 30.6-83.1ng/mL] and correlated with male gender, older age, comorbidities, other severity biomarkers, and respiratory support requirements. sST2 levels were higher in patients who died (n=45, 9.1%) (45.6 [28.0, 75.9]ng/mL vs. 144 [82.6, 319] ng/mL, p<0.001) and those admitted to ICU (n=46, 9.3%) (44.7 [27.5, 71.3] ng/mL vs. 125 [69.0, 262]ng/mL, p<0.001). sST2 levels>210ng/mL were a strong predictor of complicated in-hospital courses, with higher risk of death (OR, 39.3, CI95% 15.9, 103) and death/ICU (OR 38.3, CI95% 16.3-97.5) after adjusting for all other risk factors. The addition of sST2 enhanced the predictive capacity of mortality risk models. Conclusions: sST2 represents a robust severity predictor in COVID-19 and could be an important tool for identifying at-risk patients who may benefit from closer follow-up and specific therapies.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 50 条
  • [1] A biomarker for bacteremia in pregnant women with acute pyelonephritis: soluble suppressor of tumorigenicity 2 or sST2
    Chatterton, Carolyn
    Romero, Roberto
    Jung, Eunjung
    Gallo, Dahiana M.
    Suksai, Manaphat
    Diaz-Primera, Ramiro.
    Erez, Offer
    Chaemsaithong, Piya
    Tarca, Adi L.
    Gotsch, Francesca
    Bosco, Mariachiara
    Chaiworapongsa, Tinnakorn
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2023, 36 (01):
  • [2] Serum sST2: key biomarker in COVID-19 patients with implications for coronary artery disease
    Xueqin Li
    Yaxin Tian
    Hongyan Cao
    Jinfang Cheng
    BMC Infectious Diseases, 25 (1)
  • [3] Dowe need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2)
    Maisel, Alan S.
    Di Somma, Salvatore
    EUROPEAN HEART JOURNAL, 2017, 38 (30) : 2325 - 2332A
  • [4] The progress of the soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation
    Liu, Jia-Hui
    Han, Qian-Feng
    Mo, De-Gang
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2022, 65 (03) : 591 - 592
  • [5] The progress of the soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation
    Jia-Hui Liu
    Qian-Feng Han
    De-Gang Mo
    Journal of Interventional Cardiac Electrophysiology, 2022, 65 : 591 - 592
  • [6] Is soluble supression of tumorigenicity (sST2) a new biomarker in patients with right ventricular failure due to pulmonary hypertension?
    Banaszkiewicz, M.
    Darocha, S.
    Pietrasik, A.
    Norwa, J.
    Dobosiewicz, A.
    Kepski, J.
    Florczyk, M.
    Manczak, R.
    Torbicki, A.
    Kurzyna, M.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1150 - 1150
  • [7] sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial
    David M. Smadja
    Clément R. Massonnaud
    Aurélien Philippe
    Mickael Rosa
    Sophie Luneau
    Antoine Rauch
    Nathan Peiffer-Smadja
    Amandine Gagneux-Brunon
    Julien Poissy
    Maxime Gruest
    Alexandre Ung
    Valérie Pourcher
    François Raffi
    Lionel Piroth
    Kévin Bouiller
    Hélène Esperou
    Christelle Delmas
    Drifa Belhadi
    Alpha Diallo
    Juliette Saillard
    Aline Dechanet
    Noémie Mercier
    Axelle Dupont
    François-Xavier Lescure
    François Goehringer
    Stéphane Jaureguiberry
    François Danion
    Violaine Tolsma
    André Cabie
    Johan Courjon
    Sylvie Leroy
    Joy Mootien
    Bruno Mourvillier
    Sébastien Gallien
    Jean-Philippe Lanoix
    Elisabeth Botelho-nevers
    Florent Wallet
    Jean-Christophe Richard
    Jean Reuter
    Alexandre Gaymard
    Richard Greil
    Guillaume Martin-Blondel
    Claire Andrejak
    Yazdan Yazdanpanah
    Charles Burdet
    Jean-Luc Diehl
    Maya Hites
    Florence Ader
    Sophie Susen
    France Mentré
    Scientific Reports, 15 (1)
  • [8] Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
    Hildenbrand, Florian F.
    Illi, Barbara
    von Felten, Stefanie
    Bachofner, Jacqueline
    Gawinecka, Joanna
    von Eckardstein, Arnold
    Mullhaupt, Beat
    Mertens, Joachim C.
    Blumel, Sena
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [9] Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
    Florian F. Hildenbrand
    Barbara Illi
    Stefanie von Felten
    Jacqueline Bachofner
    Joanna Gawinecka
    Arnold von Eckardstein
    Beat Müllhaupt
    Joachim C. Mertens
    Sena Blümel
    BMC Gastroenterology, 24
  • [10] Soluble Suppression of Tumorigenicity-2 (sst2) Predicts Mortality and Right Heart Failure in Lvad Patients
    Numan, L.
    Aarts, E.
    Ramjankhan, F.
    Van der Meer, M. G.
    Oerlemans, M.
    De Jonge, N.
    Oppelaar, A.
    Kemperman, H.
    Asselbergs, F.
    Van Laake, L. W.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S364 - S365